Jmac Enterprises LLC Grows Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Jmac Enterprises LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 96,671 shares of the medical research company’s stock after acquiring an additional 121 shares during the period. Amgen accounts for 5.0% of Jmac Enterprises LLC’s holdings, making the stock its 4th largest position. Jmac Enterprises LLC’s holdings in Amgen were worth $31,148,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in AMGN. Strategic Financial Concepts LLC acquired a new position in shares of Amgen in the second quarter valued at about $26,000. Hershey Financial Advisers LLC bought a new stake in Amgen in the 2nd quarter valued at about $30,000. nVerses Capital LLC acquired a new position in shares of Amgen during the 2nd quarter worth approximately $31,000. Bbjs Financial Advisors LLC bought a new position in shares of Amgen during the second quarter worth approximately $33,000. Finally, Matrix Trust Co acquired a new stake in shares of Amgen in the third quarter valued at approximately $36,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 0.9 %

Shares of NASDAQ AMGN opened at $319.04 on Thursday. The company’s fifty day simple moving average is $323.96 and its 200 day simple moving average is $316.68. Amgen Inc. has a 12-month low of $260.52 and a 12-month high of $346.85. The firm has a market cap of $171.43 billion, a PE ratio of 41.20, a P/E/G ratio of 2.81 and a beta of 0.60. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter in the previous year, the company posted $4.96 earnings per share. The company’s quarterly revenue was up 23.2% on a year-over-year basis. As a group, sell-side analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.82%. Amgen’s dividend payout ratio is presently 115.24%.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of analyst reports. StockNews.com raised Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Sanford C. Bernstein started coverage on shares of Amgen in a research note on Thursday, October 17th. They set an “outperform” rating and a $380.00 price objective on the stock. Oppenheimer reissued an “outperform” rating and set a $380.00 price target on shares of Amgen in a report on Wednesday, August 7th. Barclays increased their price objective on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Finally, Dbs Bank raised Amgen to a “strong-buy” rating in a research note on Monday, September 16th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $333.50.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.